LACE trial: Laparoscopy vs. Open for Endometrial Cancer
Among women with stage I endometrial cancer, TLH is equivalent to TAH in terms of disease-free survival, supporting the use of laparoscopic surgery.
Study Summaries
GOG 33: Surgical Pathologic Spread Patterns of Endometrial Cancer
Surgical pathology effectively identifies prognostic factors and spread patterns in Stage I endometrial carcinoma, supporting individualized postoperative therapy based on pathologic findings.
Checkmate 0358: Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer
Nivolumab alone or in combination with ipilimumab shows promise in recurrent or metastatic cervical cancer, with significant objective response rates and manageable safety profiles.
GOG-LAP2: Laparoscopy Compared With Laparotomy for Endometrial Cancer Staging
Laparoscopic surgical staging for uterine cancer is feasible and safe, showing fewer complications and shorter hospital stays compared to laparotomy
OV-HIPEC 1: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
The addition of HIPEC to interval cytoreductive surgery for stage III epithelial ovarian cancer significantly improves recurrence-free and overall survival without an increase in severe side effects.
GOG 279: Cisplatin, Gemcitabine, and IMRT for Locally Advanced Vulvar Carcinoma
Weekly Cisplatin and Gemcitabine concurrent with IMRT improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical resection.
GOG 261: Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Carcinosarcoma
Carboplatin/Taxol is not inferior to Ifos/Taxol in terms of OS and significantly increases PFS, making it a new standard treatment for carcinosarcoma
KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival compared to chemoradiotherapy alone
CALLA: Durvalumab versus placebo with chemoradiotherapy
Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer
SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer
Neoadjuvant chemotherapy and primary debulking surgery showed similar efficacy in terms of progression-free and overall survival. However, neoadjuvant chemotherapy resulted in significantly lower rates of post-operative complications, suggesting a different toxicity profile